Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells
Abstract
Background and purpose
Resistance of pancreatic ductal adenocarcinoma (PDAC) to chemo- and radiotherapy is a major obstacle. The integral membrane protein Caveolin-1 (Cav-1) has been suggested as a potent target in human pancreatic carcinoma cells.
Materials and methods
Human pancreatic tumor cells were examined in a three-dimensional (3D) cell culture model with regard to clonogenic survival, apoptosis, radiogenic DNA-double strand breaks and protein expression and phosphorylation under siRNA-mediated knockdown of Cav-1 without and in combination with irradiation (X-rays, 0–6
Gy). Immunohistochemistry was used to assess Cav-1 expression in biopsies from patients with PDAC.
Results
Tumor cells in PDAC showed significantly higher Cav-1 expression relative to tumor stroma. Cav-1 knockdown significantly reduced β1 integrin expression and Akt phosphorylation, induced Caspase 3- and Caspase 8-dependent apoptosis and enhanced the radiosensitivity of 3D cell cultures. While cell cycling and Cav-1 promoter activity remained stable, Cav-1 knockdown-induced radiosensitization correlated with elevated numbers of residual DNA-double strand breaks.
Conclusions
Our data strongly support the concept of Cav-1 as a potent target in pancreatic carcinoma cells due to radiosensitization and Cav-1 overexpression in tumor cells of PDAC. 3D cell cultures are powerful and useful tools for the testing of novel targeting strategies to optimize conventional radio- and chemotherapy regimes for PDAC.
Abbreviations: Cav-1, Caveolin-1, DNA-DSB, DNA-double strand break, ECM, extracellular matrix, FAK, focal adhesion kinase, GSK3β, glycogen synthase kinase-3β, ILK, integrin-linked kinase, IP, immunoprecipitation, lrECM, laminin-rich extracellular matrix, PINCH-1, particularly interesting new cysteine–histidine-rich protein 1, rDNA-DSB, residual DNA-double strand break
Keywords: Caveolin-1, β1 integrin, Ionizing radiation, Three-dimensional cell culture, Pancreatic carcinoma
To access this article, please choose from the options below
PII: S0167-8140(09)00393-4
doi:10.1016/j.radonc.2009.07.004
© 2009 Elsevier Ireland Ltd. All rights reserved.
